395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)

Choueiri, T.K.; Escudier, Bernard; Pál, Siklós; Jonasch, Eric; Heng, Daniel Yick Chin; Powles, T.; Arkenau, H-T.; Clark, Elizabeth Bourquardez; D’Cruz, Celina M.; Frigault, Melanie M.; Nash, A.F.; Morgan, S.

doi:10.1016/s0959-8049(14)70521-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rationale for targeting MET in pRCC was previously demonstrated in a phase II trial with foretinib, a dual MET/VEGFR2 inhibitor, that produced an RR of 13.5% and a median PFS of 9.3 months . Volitinib's targeting of MET has also demonstrated potential utilization according to preliminary phase I/II trial results (NCT02127710); a phase III trial is planned . Additionally, it is likely that PD‐L1 inhibitors will be tested in pRCC in the near future, given evidence that ~10% of pRCC tumors express PD‐L1, and these patients appear to have worse outcomes than PD‐L1 negative tumors .…”

Section: Discussionmentioning

confidence: 99%

Characterizing the outcomes of metastatic papillary renal cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression‐free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC. OS was 8 months longer in ccRCC patients and the hazard ratio of death was 0.71 for ccRCC patients. No differences in PFS or ORR were detected between type I and II PRCC in this limited dataset. The median OS for type I pRCC was 20.0 months while the median OS for type II was 12.6 months (P = 0.096). The IMDC prognostic model was able to stratify pRCC patients into favorable risk (OS = 34.1 months), intermediate risk (OS = 17.0 months), and poor‐risk groups (OS = 6.0 months). pRCC patient outcomes were inferior to ccRCC, even after controlling for IMDC prognostic factors. The IMDC prognostic model was able to effectively stratify pRCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%